GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Shares Outstanding (EOP)

Sangui Biotech International (Sangui Biotech International) Shares Outstanding (EOP) : 209.90 Mil (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sangui Biotech International's shares outstanding for the quarter that ended in Mar. 2023 was 209.90 Mil.

Sangui Biotech International's quarterly shares outstanding stayed the same from Dec. 2022 (209.90 Mil) to Mar. 2023 (209.90 Mil).

Sangui Biotech International's annual shares outstanding increased from Jun. 2021 (206.90 Mil) to Jun. 2022 (209.90 Mil). It means Sangui Biotech International issued new shares from Jun. 2021 to Jun. 2022 .


Sangui Biotech International Shares Outstanding (EOP) Historical Data

The historical data trend for Sangui Biotech International's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Shares Outstanding (EOP) Chart

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 191.90 199.24 203.30 206.90 209.90

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 206.90 209.90 209.90 209.90 209.90

Competitive Comparison of Sangui Biotech International's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Shares Outstanding (EOP) falls into.



Sangui Biotech International Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Sangui Biotech International  (OTCPK:SGBI) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Sangui Biotech International Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (Sangui Biotech International) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines